New HQ and research center for Juno Therapeutics

US biotech Juno Therapeutics has unveiled its new headquarters and research facility, located in the heart of South Lake Union in Seattle.

Juno’s move to the headquarters and research facility comes during a momentous period for both the field of cell therapy and the company. The US Food and Drug Administration approved the first chimeric antigen receptor (CAR) T therapy earlier this month, and Juno posted very encouraging data with JCAR017 in June. Juno believes data from the JCAR017 trial may support FDA approval for the treatment of aggressive non-Hodgkin jymphoma as soon as 2018. Juno also possesses a deep pipeline of other product candidates focused on a number of cancers.

The new headquarters brings together Juno’s Seattle employees – previously spread among three locations – enabling the company’s scientists, researchers, technical professionals and administrative staff to work collaboratively in a state-of-the-art facility. The company’s move signifies its investment in the science that is critical to driving developments in cell therapy.

“At Juno, our single focus is delivering on the promise of cell therapy. This is an exciting new frontier in medicine with the potential to change the way we treat cancer,” said Hans Bishop, Juno’s president and chief executive, adding: “Our new headquarters and research facility underscore our investment in this future and our commitment to deliver better treatments to our patients.”